Doxycycline for MRSA and Pseudomonas Infections

MRSA Coverage with Doxycycline

The Infectious Diseases Society of America (IDSA) recommends doxycycline as an appropriate oral antibiotic option for empirical coverage of community-acquired MRSA in outpatients with skin and soft tissue infections 3, 4
Doxycycline is considered an effective empirical therapy option for CA-MRSA pending culture results in outpatients with purulent cellulitis 4
Doxycycline is specifically listed as a treatment option for mild diabetic wound infections when MRSA is suspected or confirmed by the Infectious Diseases Society of America (IDSA) 1, 2

Doxycycline is bacteriostatic rather than bactericidal against MRSA, which may limit its use in severe infections, according to the Infectious Diseases Society of America (IDSA) 5, 6
Treatment failure rates of 21% have been reported with doxycycline or minocycline for MRSA infections, as noted by the Infectious Diseases Society of America (IDSA) 6
For hospitalized patients with complicated skin and soft tissue infections, parenteral options like vancomycin, linezolid, or daptomycin are preferred over doxycycline by the Infectious Diseases Society of America (IDSA) 3, 4
Tetracyclines including doxycycline should not be used in children under 8 years of age, as recommended by the Infectious Diseases Society of America (IDSA) and the American Academy of Pediatrics 3, 4

Doxycycline has no reliable activity against Pseudomonas aeruginosa, according to the Clinical Microbiology and Infection guidelines 1, 2
For suspected or confirmed Pseudomonas aeruginosa infections, recommended antibiotics include piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, and carbapenems, as suggested by the Clinical Microbiology and Infection guidelines 1, 2
No guidelines recommend doxycycline for Pseudomonas infections, as stated by the Clinical Microbiology and Infection guidelines and the Infectious Diseases Society of America (IDSA) 1, 2, 7

When empirically treating skin and soft tissue infections where MRSA is suspected, doxycycline is an appropriate option, according to the Infectious Diseases Society of America (IDSA) 3, 4
If coverage for both beta-hemolytic streptococci and CA-MRSA is desired, options include clindamycin alone or doxycycline in combination with a beta-lactam (e.g., amoxicillin), as recommended by the Infectious Diseases Society of America (IDSA) 4
For patients with suspected or confirmed Pseudomonas infections, alternative antibiotics with anti-pseudomonal activity must be used, such as those recommended by the Clinical Microbiology and Infection guidelines 1, 2
In cases where both MRSA and Pseudomonas coverage is needed, combination therapy would be required, as no single oral agent adequately covers both pathogens, according to the Clinical Microbiology and Infection guidelines and the Infectious Diseases Society of America (IDSA) 1, 2

Always obtain appropriate cultures before starting antibiotics when possible, especially in moderate to severe infections, as recommended by the Infectious Diseases Society of America (IDSA) 4
Reevaluate patients within 24-48 hours when using doxycycline for suspected MRSA infections to verify clinical response, according to the Infectious Diseases Society of America (IDSA) 6
For severe infections requiring hospitalization, parenteral therapy with agents like vancomycin is typically recommended initially rather than oral doxycycline, as suggested by the Infectious Diseases Society of America (IDSA) and the American College of Emergency Physicians 3, 4